Mark Willig has over twenty-five years of experience as an executive in the Life Sciences space, with both Fortune 100 and early-stage companies including Abbott Laboratories, Thermo Fisher Scientific, and Myriad Genetics. At Thermo Fisher, Mark had global responsibility for a $300MM division, while at Myriad, he led the company to a $1B valuation in five years. Mark has also served as Chief Executive Officer at PrognostiX and General Manager at Exiqon A/S, which he led to acquisition. Most recently, Mark served as Chief Commercial Officer for Curative, the largest COVID-19 PCR testing company in the US, achieving more than $1B in revenue in its first year of operations.

Ron Keith is a career engineering, manufacturing, and supply chain executive, with over 25 years of experience, and currently serves Alveo Technologies as its Executive Vice President of Manufacturing and Supply Chains. He is the founder and Executive Director of Supply Chain Resources Group, which provides manufacturing and supply chain services in six countries to the world’s leading tech product companies and most promising start-ups, and has consulted on product operations, manufacturing, strategy, and supply chain in 22 different countries for more than 100 companies, including a dozen global Fortune 500 companies.

Mona Patel is the Vice President of Clinical Affairs at Alveo Technologies, where she oversees Alveo’s clinical and human factors strategies supporting both registrational and nonregistrational programs. In addition, Mona leads Alveo’s product labeling, user experience (UX), and user interface (UI) initiatives.

Mona joined Alveo with over 20 years of R&D and clinical research experience within the IVD industry. For the past 16 years, she has been strategically defining, designing, and executing clinical programs in support of successful regulatory and commercial strategies for diagnostic companies such as Abbott, Cepheid, and Roche.

Doug Hart leads Alveo’s Business Development, Sales and Marketing, efforts, driving the company’s commercial and go-to-market strategies. Doug earned a bachelor of science in electronic engineering technology from the University of Southern Mississippi and is a successful leader with over 20 years of leadership experience in business development and marketing, driving company growth, strategy, and relationship management and creating value for healthcare, technology, and consumer product companies.

Most recently, Doug served as Senior Director of Business Development for Integrated Healthcare Association (IHA), where he led the business development division and managed and negotiated regional multimillion-dollar contracts. Prior to joining IHA, Doug held leadership positions with Florida Blue, Deloitte Consulting, MedeAnalytics, and McKesson, focusing on company revenue generation and client success.

Angie Aquino-Sales serves as Senior Director of People & Culture at Alveo Technologies, where she is focused on human resources strategic planning and organizational design, building HR functions, and designing talent programs for leader and employee development.

Prior to joining Alveo, Angie served at Prologis as a Senior Human Resources Business Partner, at OptiScan Biomedical as Head of HR, and at Tripping.com as Director of HR. Angie has experience working in start-ups and small businesses in a variety of industries. She has held related roles in large organizations including Kaiser Permanente, Blue Shield of California, and McKesson.

Ian Smith is a financial executive with over 25 years of controllership experience. His experience includes building and scaling financial operations for high-growth companies, and he has participated in numerous rounds of fundraising, M&A transactions, and public offerings. Prior to joining Alveo, Ian held leadership positions at Blackthorn Therapeutics (now Neumora) and Biomarin.

Kevin Gunning oversees Alveo’s Quality Management System and holds more than 25 years of experience working in the medical device, pharmaceutical, biotechnology, and clinical laboratory industries.

Kevin has successfully developed, implemented, and managed quality systems for a number of organizations, ranging from fledgling start-ups to established global corporations. He holds a bachelor’s degree in biological sciences from State University of New York at Buffalo and is an ASQ-certified Quality Auditor.

Alex Chang, MSc, MBA, RAC, represents regulatory affairs in the design, development, and regulatory submissions for Alveo’s COVID-19 and infectious disease products. Alex oversees Alveo’s regulatory affairs for the US, EU, and UK and will be leading regulatory efforts for global expansion into other markets.

Alex has over 22 years of broad industry experience and has been in the field of regulatory affairs since 2003, working predominantly in the medical device and diagnostics sector. Alex has held senior level roles at Singulex and Allergan, and has also worked for notable diagnostic companies including Celera Diagnostics and Novartis.  As the founder of his own consulting company, Alex has consulted for over 10+ companies, including Apple and Thermo Fisher, and has advised numerous start-ups in their regulatory strategies.

For 40 years, Michael Marks has successfully led and transformed technology companies. He is a founding managing partner at Celesta Capital, where he co-leads the firm. From 2007 to 2019, he was a founding partner at Riverwood Capital Management, a private equity fund specializing in rapidly growing private companies in North America and emerging markets. He was a partner and senior advisor at Kohlberg Kravis Roberts & Co. (KKR) in 2006 and 2007. Before KKR, he spent 13 years as Chairman and CEO of Flextronics International Ltd. and built the company into one of the largest technology companies in the world.

For 40 years, Michael Marks has successfully led and transformed technology companies. He is a founding managing partner at Celesta Capital, where he co-leads the firm. From 2007 to 2019, he was a founding partner at Riverwood Capital Management, a private equity fund specializing in rapidly growing private companies in North America and emerging markets. He was a partner and senior advisor at Kohlberg Kravis Roberts & Co. (KKR) in 2006 and 2007. Before KKR, he spent 13 years as Chairman and CEO of Flextronics International Ltd. and built the company into one of the largest technology companies in the world.

For 40 years, Michael Marks has successfully led and transformed technology companies. He is a founding managing partner at Celesta Capital, where he co-leads the firm. From 2007 to 2019, he was a founding partner at Riverwood Capital Management, a private equity fund specializing in rapidly growing private companies in North America and emerging markets. He was a partner and senior advisor at Kohlberg Kravis Roberts & Co. (KKR) in 2006 and 2007. Before KKR, he spent 13 years as Chairman and CEO of Flextronics International Ltd. and built the company into one of the largest technology companies in the world.

For 40 years, Michael Marks has successfully led and transformed technology companies. He is a founding managing partner at Celesta Capital, where he co-leads the firm. From 2007 to 2019, he was a founding partner at Riverwood Capital Management, a private equity fund specializing in rapidly growing private companies in North America and emerging markets. He was a partner and senior advisor at Kohlberg Kravis Roberts & Co. (KKR) in 2006 and 2007. Before KKR, he spent 13 years as Chairman and CEO of Flextronics International Ltd. and built the company into one of the largest technology companies in the world.